Abdominal aortic aneurysm: update on pathogenesis and medical treatments

Nature Reviews Cardiology

Volumn 16, Issue 4, 2019, Pages 225-242

  Golledge, Jonathan ^a,b  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CALCIUM CHLORIDE; CALCIUM PHOSPHATE; CYCLOSPORINE; DOXYCYCLINE; ELASTASE; METFORMIN; RIVAROXABAN; SERINE PROTEINASE INHIBITOR; TELMISARTAN; TICAGRELOR; TRANSFORMING GROWTH FACTOR BETA; VALSARTAN; CARDIOVASCULAR AGENT;

ABDOMINAL AORTIC ANEURYSM; ADIPOSE DERIVED STEM CELL; AORTIC WALL; ATHEROSCLEROSIS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIOVASCULAR RISK; DISEASE BURDEN; DISEASE SEVERITY; HEMODYNAMICS; HUMAN; HUMORAL IMMUNE DEFICIENCY; MEDICATION THERAPY MANAGEMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; RODENT; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL DEPLETION; XENOGRAFT; ANIMAL; AORTIC RUPTURE; DISEASE MODEL; MOLECULARLY TARGETED THERAPY; MORTALITY; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR TARGETED THERAPY; RISK FACTORS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 85056751090     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/s41569-018-0114-9     Document Type: Review

References (206)

1. Golledge, J., Muller, J., Daugherty, A. & Norman, P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler. Thromb. Vasc. Biol. 26, 2605–2613 (2006).
2. Lederle, F. A. et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann. Intern. Med. 126, 441–449 (1997).
3. Svensjö, S. et al. Low prevalence of abdominal aortic aneurysm among 65-year-old swedish men indicates a change in the epidemiology of the disease. Circulation 124, 1118–1123 (2011).
4. Oliver-Williams, C. et al. Lessons learned about prevalence and growth rates of abdominal aortic aneurysms from a 25-year ultrasound population screening programme. Br. J. Surg. 105, 68–74 (2018).
5. Singh, K., Bønaa, K. H., Jacobsen, B. K., Bjørk, L. & Solberg, S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromsø study. Am. J. Epidemiol. 154, 236–244 (2001).
6. Jamrozik, K. et al. Screening for abdominal aortic aneurysm: lessons from a population-based study. Med. J. Aust. 173, 345–350 (2000).
7. Tang, W. et al. Lifetime risk and risk factors for abdominal aortic aneurysm in a 24-year prospective study: the ARIC study (atherosclerosis risk in communities). Arterioscler. Thromb. Vasc. Biol. 36, 2468–2477 (2016).
8. Gianfagna, F. et al. Prevalence of abdominal aortic aneurysms in the general population and in subgroups at high cardiovascular risk in Italy: results of the RoCAV population based study. Eur. J. Vasc. Endovasc. Surg. 55, 633–639 (2018).
9. Sweeting, M. J. et al. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br. J. Surg. 99, 655–665 (2012).
10. Lederle, F. A. The rise and fall of abdominal aortic aneurysm. Circulation 124, 1097–1099 (2011).
11. Ulug, P. et al. Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women. Br. J. Surg. 103, 1097–1104 (2016).
12. Sampson, U. K. A. et al. Estimation of global and regional incidence and prevalence of abdominal aortic aneurysms 1990 to 2010. Glob. Heart 9, 159–170 (2014).
13. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117–171 (2013).
14. Sampson, U. K. A. et al. Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. Glob. Heart 9, 171–180 (2014).
15. Powell, J. T. et al. Final 12-year follow-up of surgery versus surveillance in the UK small aneurysm trial. Br. J. Surg. 94, 702–708 (2007).
16. Lederle, F. A. et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N. Engl. J. Med. 346, 1437–1444 (2002).
17. Parkinson, F. et al. Rupture rates of untreated large abdominal aortic aneurysms in patients unfit for elective repair. J. Vasc. Surg. 61, 1606–1612 (2015).
18. Lederle, F. A. et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 287, 2968–2972 (2002).
19. Chaikof, E. L. et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J. Vasc. Surg. 67, 2–77.e2 (2018).
20. Moll, F. L. et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur. J. Vasc. Endovasc. Surg. 41, S1–S58 (2011).
21. Cao, P. et al. Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial. Eur. J. Vasc. Endovasc. Surg. 41, 13–25 (2010).
22. Ouriel, K., Clair, D. G., Kent, K. C. & Zarins, C. K. & PIVOTAL Investigators. Endovascular repair compared with surveillance for patients with small abdominal aortic aneurysms. J. Vasc. Surg. 51, 1081–1087 (2010).
23. IMPROVE Trial Investigators. Comparative clinical effectiveness and cost effectiveness of endovascular strategy v open repair for ruptured abdominal aortic aneurysm: three year results of the IMPROVE randomised trial. BMJ 359, j4859 (2017).
24. Powell, J. T. et al. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 Years. J. Vasc. Surg. 65, 1539–1540 (2017).
25. Michel, M. et al. A study of the cost-effectiveness of fenestrated/branched EVAR compared with open surgery for patients with complex aortic aneurysms at 2 years. Eur. J. Vasc. Endovasc. Surg. 56, 15–21 (2018).
26. Sweeting, M. J., Patel, R., Powell, J. T., Greenhalgh, R. M. & EVAR Trial Investigators. Endovascular repair of abdominal aortic aneurysm in patients physically ineligible for open repair: very long-term follow-up in the EVAR-2 randomized controlled trial. Ann. Surg. 266, 713–719 (2017).
27. Buck, D. B., Van Herwaarden, J. A., Schermerhorn, M. L. & Moll, F. L. Endovascular treatment of abdominal aortic aneurysms. Nat. Rev. Cardiol. 11, 112–123 (2014).
28. Filardo, G., Powell, J. T., Martinez, M. A., Martinez, M. A. & Ballard, D. J. Surgery for small asymptomatic abdominal aortic aneurysms. Cochrane Database Syst. Rev. 3, CD001835 (2015).
29. Kokje, V. B. C., Hamming, J. F. & Lindeman, J. H. N. Pharmaceutical management of small abdominal aortic aneurysms: a systematic review of the clinical evidence. Eur. J. Vasc. Endovasc. Surg. 50, 702–713 (2015).
30. Rughani, G., Robertson, L. & Clarke, M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst. Rev. 9, CD009536 (2012).
31. Golledge, J. & Norman, P. E. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 217, 57–63 (2011).
32. The UK Small Aneurysm Trial Participants. Health service costs and quality of life for early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 352, 1656–1660 (1998).
33. Daugherty, A., Manning, M. W. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105, 1605–1612 (2000).
34. Alsiraj, Y. et al. Female mice with an XY sex chromosome complement develop severe angiotensin II–induced abdominal aortic aneurysms. Circulation 135, 379–391 (2017).
35. Wang, S. et al. Activation of AMP-activated protein kinase α2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. Nat. Med. 18, 902–910 (2012).
36. −/− mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am. J. Pathol. 179, 1542–1548 (2011).
37. Rush, C. et al. Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics 10, 298–298 (2009).
38. −/− ) mice: a model for aortic dissection rather than abdominal aortic aneurysm? Cardiovasc. Res. 113, 1230–1242 (2007).
39. Trachet, B. et al. Ascending aortic aneurysm in angiotensin II–infused mice: formation, progression, and the role of focal dissections. Arterioscler. Thromb. Vasc. Biol. 36, 673–681 (2016).
40. Moran, C. S. et al. Resveratrol inhibits growth of experimental abdominal aortic aneurysm associated with upregulation of angiotensin-converting enzyme 2. Arterioscler. Thromb. Vasc. Biol. 37, 2195–2195 (2017).
41. Yu, M., Chen, C., Cao, Y. & Qi, R. Inhibitory effects of doxycycline on the onset and progression of abdominal aortic aneurysm and its related mechanisms. Eur. J. Pharmacol. 811, 101–109 (2017).
42. Busch, A. et al. Extra- and intraluminal elastase induce morphologically distinct abdominal aortic aneurysms in mice and thus represent specific subtypes of human disease. J. Vasc. Res. 53, 49–57 (2016).
43. Johnston, W. F. et al. Aromatase is required for female abdominal aortic aneurysm protection. J. Vasc. Surg. 61, 1565–1574 (2015).
44. Bergoeing, M. P. et al. Cigarette smoking increases aortic dilatation without affecting matrix metalloproteinase-9 and -12 expression in a modified mouse model of aneurysm formation. J. Vasc. Surg. 45, 1217–1227 (2007).
45. Steinmetz, E. F. et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann. Surg. 241, 92–101 (2005).
46. Busch, A. et al. Four surgical modifications to the classic elastase perfusion aneurysm model enable haemodynamic alterations and extended elastase perfusion. Eur. J. Vasc. Endovasc. Surg. 56, 102–109 (2018).
47. Wang, Y., Krishna, S. & Golledge, J. The calcium chloride-induced rodent model of abdominal aortic aneurysm. Atherosclerosis 226, 29–39 (2012).
48. Wang, Y. et al. Influence of apolipoprotein E, age and aortic site on calcium phosphate induced abdominal aortic aneurysm in mice. Atherosclerosis 235, 204–212 (2014).
49. Franck, G. et al. Reestablishment of the endothelial lining by endothelial cell therapy stabilizes experimental abdominal aortic aneurysms. Circulation 127, 1877–1887 (2013).
50. Schneider, F. et al. Bone marrow mesenchymal stem cells stabilize already-formed aortic aneurysms more efficiently than vascular smooth muscle cells in a rat model. Eur. J. Vasc. Endovasc. Surg. 45, 666–672 (2003).
51. Coscas, R. et al. Exploring antibody-dependent adaptive immunity against aortic extracellular matrix components in experimental aortic aneurysms. J. Vasc. Surg. 138, 1551–1568 (2018).
52. Lu, G. et al. A novel chronic advanced stage abdominal aortic aneurysm murine model. J. Vasc. Surg. 66, 232–242 (2016).
53. Lareyre, F. et al. TGFβ (transforming growth factor-β) blockade induces a human-like disease in a nondissecting mouse model of abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 37, 2171–2171 (2017).
54. Riber, S. S. et al. Induction of autoimmune abdominal aortic aneurysm in pigs — a novel large animal model. Ann. Med. Surg. 20, 26–31 (2017).
55. Sénémaud, J. et al. Translational relevance and recent advances of animal models of abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 37, 401–410 (2017).
56. Marinov, G. R. et al. Can the infusion of elastase in the abdominal aorta of the Yucatán miniature swine consistently produce experimental aneurysms? J. Invest. Surg. 10, 129–150 (1997).
57. Wanhainen, A., Mani, K. & Golledge, J. Surrogate markers of abdominal aortic aneurysm progression. Arterioscler. Thromb. Vasc. Biol. 36, 236–244 (2016).
58. Golledge, J., Norman, P. E., Murphy, M. P. & Dalman, R. L. Challenges and opportunities in limiting abdominal aortic aneurysm growth. J. Vasc. Surg. 65, 225–233 (2016).
59. Walker, D. I., Bloor, K., Williams, G. & Gillie, I. Inflammatory aneurysms of the abdominal aorta. Br. J. Surg. 59, 609–614 (1972).
60. Spin, J. M. et al. Transcriptional profiling and network analysis of the murine angiotensin II-induced abdominal aortic aneurysm. Physiol. Genomics 43, 993–1003 (2011).
61. Uchida, H. A. et al. Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Atherosclerosis 211, 399–403 (2010).
62. Furusho, A. et al. Involvement of B cells, immunoglobulins, and syk in the pathogenesis of abdominal aortic aneurysm. J. Am. Heart Assoc. 7, 1–16 (2018).
63. Meher, A. K. et al. B2 cells suppress experimental abdominal aortic aneurysms. Am. J. Pathol. 184, 3130–3141 (2014).
64. Schaheen, B. et al. B cell depletion promotes aortic infiltration of immunosuppressive cells and is protective of experimental aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 36, 2191–2202 (2016).
65. + regulatory T cells play a protective role in angiotensin II–induced aortic aneurysm formation in mice. Hypertension 65, 889–895 (2015).
66. Ait-Oufella, H. et al. Natural regulatory T cells limit angiotensin II–induced aneurysm formation and rupture in mice. Arterioscler. Thromb. Vasc. Biol. 33, 2374–2379 (2013).
67. + regulatory T cells. J. Am. Heart Assoc. 6, 1–13 (2017).
68. Zhou, Y. et al. Regulatory T cells in human and angiotensin II-induced mouse abdominal aortic aneurysms. Cardiovasc. Res. 107, 98–107 (2015).
69. Meng, X. et al. Regulatory T cells prevent angiotensin II–induced abdominal aortic aneurysm in apolipoprotein E knockout mice. Hypertension 64, 875–882 (2014).
70. van Puijvelde, G. et al. CD1d deficiency inhibits the development of abdominal aortic aneurysms in LDL receptor deficient mice. PLOS ONE 13, e0190962 (2018).
71. Zhang, S. et al. Deficiency of γδT cells protects against abdominal aortic aneurysms by regulating phosphoinositide 3-kinase/AKT signalling. J. Vasc. Surg. 67, 899–908 (2016).
72. Tsuruda, T. et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ. Res. 102, 1368–1377 (2008).
73. + T cells, mast cells, and macrophages participate in the pathogenesis of experimental abdominal aortic aneurysms. EMBO Mol. Med. 6, 952–969 (2014).
74. Eliason, J. L. et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation 112, 232–240 (2005).
75. Meng, X. et al. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 13, 167–179 (2015).
76. Zhang, J. et al. Mast cell tryptase deficiency attenuates mouse abdominal aortic aneurysm formation. Circ. Res. 108, 1316–1327 (2011).
77. Sun, J. et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 120, 973–982 (2009).
78. Liu, C. et al. Allergic lung inflammation aggravates angiotensin II–induced abdominal aortic aneurysms in mice. Arterioscler. Thromb. Vasc. Biol. 36, 69–77 (2016).
79. Koole, D. et al. Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. Arterioscler. Thromb. Vasc. Biol. 32, 1497–1504 (2012).
80. Golledge, A. L. V., Walker, P., Norman, P. E. & Golledge, J. A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis. Markers 26, 181–188 (2009).
81. Lindeman, J. H. N., Rabelink, T. J. & Van Bockel, J. H. Immunosuppression and the abdominal aortic aneurysm: Doctor Jekyll or Mister Hyde? Circulation 124, 463–465 (2011).
82. Biros, E. et al. Differential gene expression in human abdominal aortic aneurysm and aortic occlusive disease. Oncotarget 6, 12984–12996 (2015).
83. Biros, E. et al. Differential gene expression in the proximal neck of human abdominal aortic aneurysm. Atherosclerosis 233, 211–218 (2014).
84. Forester, N. D., Cruickshank, S. M., Scott, D. J. A. & Carding, S. R. Functional characterization of T cells in abdominal aortic aneurysms. Immunology 115, 262–270 (2005).
85. Lu, S. et al. Aneurysmal lesions of patients with abdominal aortic aneurysm contain clonally expanded t cells. J. Immunol. 192, 4897–4912 (2014).
86. + T regulatory cell function in patients with abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 30, 1825–1831 (2010).
87. Golledge, J., Tsao, P. S., Dalman, R. L. & Norman, P. E. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 118, 2382–2392 (2008).
88. Harrison, S. et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur. Heart J. 34, 3707–3716 (2013).
89. Brittenden, J. et al. Aortic wall inflammation predicts abdominal aortic aneurysm expansion, rupture, and need for surgical repair. Circulation 136, 787–797 (2017).
90. Tajima, Y. et al. Oral steroid use and abdominal aortic aneurysm expansion — positive association. Circ. J. 81, 1774–1782 (2017).
91. Sillesen, H. et al. Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm. Br. J. Surg. 102, 894–901 (2015).
92. Arnoud Meijer, C. et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann. Intern. Med. 159, 815–823 (2013).
93. Lindeman, J. H. N., Abdul-Hussien, H., Van Bockel, J. H., Wolterbeek, R. & Kleemann, R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm doxycycline selectively depletes aortic wall neutrophils and cytotoxic t cells. Circulation 119, 2209–2216 (2009).
94. Golledge, J. & Norman, P. E. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Arterioscler. Thromb. Vasc. Biol. 30, 1075–1077 (2010).
95. Ward, M. R., Pasterkamp, G., Yeung, A. C. & Borst, C. Arterial remodeling: mechanisms and clinical implications. Circulation 102, 1186–1191 (2000).
96. Kasashima, S. et al. Upregulated interleukins (IL-6, IL-10, and IL-13) in immunoglobulin G4-related aortic aneurysm patients. J. Vasc. Surg. 67, 1248–1262 (2017).
97. Moran, C. S. et al. Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis. Sci. Rep. 7, 1–12 (2017).
98. Krishna, S. M. et al. Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II–induced aortic aneurysm and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 37, 553–566 (2017).
99. Umebayashi, R. et al. Cilostazol attenuates angiotensin II-induced abdominal aortic aneurysms but not atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 38, 903–912 (2018).
100. Dale, M. A. et al. Background differences in baseline and stimulated MMP levels influence abdominal aortic aneurysm susceptibility. Atherosclerosis 243, 621–629 (2015).
101. Yao, L. et al. Association of carotid atherosclerosis and stiffness with abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 270, 110–116 (2018).
102. Matthews, E. O. et al. Meta-analysis of the association between peripheral artery disease and growth of abdominal aortic aneurysms. J. Vasc. Surg. 67, 674–674 (2018).
103. Takagi, H. & Umemoto, T. & ALICE Group. Association of peripheral artery disease with abdominal aortic aneurysm growth. J. Vasc. Surg. 64, 506–513 (2016).
104. Brady, A. R. et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110, 16–21 (2014).
105. Michel, J. et al. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc. Res. 90, 18–27 (2011).
106. Owens, I. et al. Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 35, 2032–2041 (2015).
107. Dai, J., Louedec, L., Philippe, M., Michel, J. B. & Houard, X. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model. J. Vasc. Surg. 49, 719–727 (2009).
108. Fontaine, V. et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am. J. Pathol. 161, 1701–1710 (2002).
109. Golledge, J., Wolanski, P., Parr, A. & Buttner, P. Measurement and determinants of infrarenal aortic thrombus volume. Eur. Radiol. 18, 1987–1994 (2008).
110. Nguyen, V. L. et al. Abdominal aortic aneurysms with high thrombus signal intensity on magnetic resonance imaging are associated with high growth rate. Eur. J. Vasc. Endovasc. Surg. 48, 676–684 (2014).
111. Behr-Rasmussen, C., Grøndal, N., Bramsen, M. B., Thomsen, M. D. & Lindholt, J. S. Mural thrombus and the progression of abdominal aortic aneurysms: a large population-based prospective cohort study. Eur. J. Vasc. Endovasc. Surg. 48, 301–307 (2014).
112. Parr, A. et al. Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneurysms. J. Vasc. Surg. 53, 28–35 (2011).
113. Lindholt, J. S., Jørgensen, B., Fasting, H. & Henneberg, E. W. Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes. J. Vasc. Surg. 34, 611–615 (2001).
114. Golledge, J., Muller, R., Clancy, P., McCann, M. & Norman, P. E. Evaluation of the diagnostic and prognostic value of plasma D-dimer for abdominal aortic aneurysm. Eur. Heart J. 32, 354–364 (2011).
115. Vega de Ceniga, M. et al. Assessment of biomarkers and predictive model for short-term prospective abdominal aortic aneurysm growth — a pilot study. Ann. Vasc. Surg. 28, 1642–1648 (2014).
116. Arzani, A., Suh, G., Dalman, R. L. & Shadden, S. C. A. A longitudinal comparison of hemodynamics and intraluminal thrombus deposition in abdominal aortic aneurysms. Am. J. Physiol. Heart Circ. Physiol. 307, H1786–H1795 (2014).
117. Golledge, J. et al. Thrombus volume is similar in patients with ruptured and intact abdominal aortic aneurysms. J. Vasc. Surg. 59, 315–320 (2014).
118. Speelman, L. et al. The mechanical role of thrombus on the growth rate of an abdominal aortic aneurysm. J. Vasc. Surg. 51, 19–26 (2010).
119. Dong, S. L. et al. Aneurysm of the anomalous splenic artery arising from superior mesenteric artery treated by coil embolization: a report of two cases and literature review. Ann. Vasc. Surg. 48, 251.e5–251.e10 (2018).
120. Salata, K. et al. Statins reduce abdominal aortic aneurysm growth, rupture, and perioperative mortality: a sys tematic review and meta-analysis. J. Am. Heart Assoc. 7, e008657 (2018).
121. Joergensen, T. M. M. et al. High heritability of liability to abdominal aortic aneurysms: a population based twin study. Eur. J. Vasc. Endovasc. Surg. 52, 41–46 (2016).
122. Golledge, J. & Kuivaniemi, H. Genetics of abdominal aortic aneurysm. Curr. Opin. Cardiol. 28, 290–296 (2013).
123. Raffort, J., Lareyre, F., Clement, M. & Mallat, Z. Micro-RNAs in abdominal aortic aneurysms: insights from animal models and relevance to human disease. Cardiovasc. Res. 110, 165–177 (2016).
124. Golledge, J., Biros, E., Bingley, J., Iyer, V. & Krishna, S. M. Epigenetics and peripheral artery disease. Curr. Atheroscler. Rep. 18, 1–9 (2016).
125. Maegdefessel, L. et al. MiR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. Nat. Commun. 5, 5214 (2014).
126. Zampetaki, A. et al. Role of miR-195 in aortic aneurysmal disease. Circ. Res. 115, 857–866 (2014).
127. Kim, C. W. et al. Prevention of abdominal aortic aneurysm by anti–microRNA-712 or anti–microRNA-205 in angiotensin II–infused mice. Arterioscler. Thromb. Vasc. Biol. 34, 1412–1421 (2014).
128. Maegdefessel, L. et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci. Transl Med. 4, 122–134 (2012).
129. Maegdefessel, L. et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J. Clin. Invest. 122, 497–506 (2012).
130. Leeper, N. J. et al. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler. Thromb. Vasc. Biol. 33, 1–10 (2013).
131. Li, D. Y. et al. H19 induces abdominal aortic aneurysm development and progression. Circulation 138, 1551–1568 (2018).
132. Pahl, M. C. et al. MicroRNA expression signature in human abdominal aortic aneurysms. BMC Med. Genomics 5, 25–25 (2012).
133. Zhang, W. et al. Plasma microRNAs serve as potential biomarkers for abdominal aortic aneurysm. Clin. Biochem. 48, 988–992 (2015).
134. Iyer, V., Rowbotham, S., Biros, E., Bingley, J. & Golledge, J. A systematic review investigating the association of microRNAs with human abdominal aortic aneurysms. Atherosclerosis 261, 78–89 (2017).
135. Jones, G. T. et al. Meta-analysis of genome-wide association studies for abdominal aortic aneurysm identifies four new disease-specific risk loci. Circ. Res. 120, 341–353 (2017).
136. Harrison, S. et al. Genetic association of lipids and lipid drug targets with abdominal aortic aneurysm: a meta-analysis. JAMA Cardiol. 3, 26–33 (2018).
137. Bäck, M. et al. Biomechanical factors in the biology of aortic wall and aortic valve diseases. Cardiovasc. Res. 99, 232–241 (2013).
138. Raaz, U. et al. Segmental aortic stiffening contributes to experimental abdominal aortic aneurysm development. Circulation 131, 1783–1795 (2015).
139. Sughimoto, K. et al. Effects of arterial blood flow on walls of the abdominal aorta: distributions of wall shear stress and oscillatory shear index determined by phase-contrast magnetic resonance imaging. Heart Vessels 31, 1168–1175 (2016).
140. Nchimi, A. et al. Multifactorial relationship between 18F-fluoro-deoxy-glucose positron emission tomography signaling and biomechanical properties in unruptured aortic aneurysms. Circ. Cardiovasc. Imaging 7, 82–91 (2014).
141. Khosla, S. et al. Meta-analysis of peak wall stress in ruptured, symptomatic and intact abdominal aortic aneurysms. Br. J. Surg. 101, 1350–1357 (2014).
142. Fillinger, M. F., Marra, S. P., Raghavan, M. L. & Kennedy, F. E. Prediction of rupture risk in abdominal aortic aneurysm during observation: wall stress versus diameter. J. Vasc. Surg. 37, 724–732 (2003).
143. The Propranolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J. Vasc. Surg. 35, 72–79 (2002).
144. Bicknell, C. et al. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). Eur. Heart J. 37, 3213–3221 (2016).
145. Pinchbeck, J. L. et al. A randomized placebo-controlled trial assessing the effect of 24 weeks fenofibrate therapy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME-2 trial. J. Am. Heart Assoc. 7, e009866 (2018).
146. Morris, D. R. et al. Telmisartan in the management of abdominal aortic aneurysm (TEDY): the study protocol for a randomized controlled trial. Trials 16, 274 (2015).
147. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02070653 (2018).
148. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02225756 (2015).
149. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01904981 (2014).
150. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01756833 (2017).
151. Xiong, J., Wu, Z., Chen, C., Wei, Y. & Guo, W. Association between diabetes and prevalence and growth rate of abdominal aortic aneurysms: a meta-analysis. Int. J. Cardiol. 221, 484–495 (2016).
152. Golledge, J. et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur. Heart J. 29, 665–672 (2008).
153. Dattani, N., Sayers, R. D. & Bown, M. J. Diabetes mellitus and abdominal aortic aneurysms: a review of the mechanisms underlying the negative relationship. Diab. Vasc. Dis. Res. 15, 367–374 (2018).
154. Kubota, Y., Folsom, A. R., Pankow, J. S., Wagenknecht, L. E. & Tang, W. Diabetes-related factors and abdominal aortic aneurysm events: the atherosclerotic risk in communities study. Ann. Epidemiol. 28, 102–106 (2018).
155. Le, M. T. Q., Jamrozik, K., Davis, T. M. E. & Norman, P. E. Negative association between infra-renal aortic diameter and glycaemia: the Health in Men study. Eur. J. Vasc. Endovasc. Surg. 33, 599–604 (2007).
156. Kristensen, K. L., Dahl, M., Rasmussen, L. M. & Lindholt, J. S. Glycated hemoglobin is associated with the growth rate of abdominal aortic aneurysms: a substudy from the VIVA (Viborg vascular) randomized screening trial. Arterioscler. Thromb. Vasc. Biol. 37, 730–736 (2017).
157. Morris, D. R. et al. The association of blood glucose and diabetes with peripheral arterial disease involving different vascular territories: results from 628 246 people who attended vascular screening. Eur. Heart J. 38, 654 (2017).
158. Vasamsetti, S. B. et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 64, 2028–2041 (2015).
159. Fujimura, N. et al. Metformin treatment status and abdominal aortic aneurysm disease progression. J. Vasc. Surg. 64, 46–54 (2016).
160. Miyama, N. et al. Hyperglycemia limits experimental aortic aneurysm progression. J. Vasc. Surg. 52, 975–983 (2010).
161. Golledge, J. et al. Association between metformin prescription and growth rates of abdominal aortic aneurysms: metformin and growth rate of abdominal aortic aneurysm. Br. J. Surg. 104, 1486–1493 (2017).
162. Itoga, N. K. et al. Metformin prescription status and abdominal aortic aneurysm disease progression in the U.S. veteran population. J. Vasc. Surg. 10.1016/j.jvs.2018.06.194 (2018).
163. Golledge, J. et al. Metformin prescription is associated with a reduction in the combined incidence of surgical repair and rupture related mortality in patients with abdominal aortic aneurysm. Eur. J. Vasc. Endovasc. Surg. 10.1016/j.ejvs.2018.07.035 (2018).
164. Kristensen, K. L., Pottegård, A., Hallas, J., Rasmussen, L. M. & Lindholt, J. S. Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms. J. Vasc. Surg. 66, 768–774 (2017).
165. Hinchliffe, R. J. Metformin and abdominal aortic aneurysm. Eur. J. Vasc. Endovasc. Surg. 54, 679–680 (2017).
166. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03507413 (2018).
167. Hosoyama, K. et al. Intravenously injected human multilineage-differentiating stress-enduring cells selectively engraft into mouse aortic aneurysms and attenuate dilatation by differentiating into multiple cell types. J. Thorac. Cardiovasc. Surg. 155, 2301–2313 (2018).
168. Xie, J. et al. Human adipose-derived stem cells suppress elastase-induced murine abdominal aortic inflammation and aneurysm expansion through paracrine factors. Cell Transplant. 26, 173–189 (2017).
169. Blose, K. J. et al. Periadventitial adipose-derived stem cell treatment halts elastase-induced abdominal aortic aneurysm progression. Regen. Med. 9, 733–741 (2014).
170. Sharma, A. K. et al. Mesenchymal stem cells attenuate NADPH oxidase-dependent high mobility group box 1 production and inhibit abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 36, 908–918 (2016).
171. Davis, J. P. et al. Attenuation of aortic aneurysms with stem cells from different genders. J. Surg. Res. 199, 249–258 (2015).
172. Yamawaki-Ogata, A. et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells in formed aortic aneurysms of a mouse model. Eur. J. Cardiothorac. Surg. 45, 156–165 (2014).
173. Fu, X. et al. Intravenous administration of mesenchymal stem cells prevents angiotensin II-induced aortic aneurysm formation in apolipoprotein E-deficient mouse. J. Transl Med. 11, 175–175 (2013).
174. Hashizume, R., Yamawaki-Ogata, A., Ueda, Y., Wagner, W. R. & Narita, Y. Mesenchymal stem cells attenuate angiotensin II-induced aortic aneurysm growth in apolipoprotein E-deficient mice. J. Vasc. Surg. 54, 1743–1752 (2011).
175. Park, H. S. et al. Potential role of vascular smooth muscle cell-like progenitor cell therapy in the suppression of experimental abdominal aortic aneurysms. Biochem. Biophys. Res. Commun. 431, 326–331 (2013).
176. Sharma, A. K. et al. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 126, S38–S45 (2012).
177. Swaminathan, G. et al. Pro-elastogenic effects of bone marrow mesenchymal stem cell-derived smooth muscle cells on cultured aneurysmal smooth muscle cells: stem cell induced elastogenesis by aneurysmal smooth muscle cells. J. Tissue Eng. Regen. Med. 11, 679–693 (2017).
178. Wang, S. K. et al. Rationale and design of the ARREST trial investigating mesenchymal stem cells in the treatment of small abdominal aortic aneurysm. Ann. Vasc. Surg. 47, 230–237 (2018).
179. Schepers, D. et al. A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3. Hum. Mutat. 39, 621–634 (2018).
180. Milewicz, D. M., Prakash, S. K. & Ramirez, F. Therapeutics targeting drivers of thoracic aortic aneurysms and acute aortic dissections: insights from predisposing genes and mouse models. Annu. Rev. Med. 68, 51–67 (2017).
181. Mallat, Z., Ait-Oufella, H. & Tedgui, A. The pathogenic transforming growth factor-beta overdrive hypothesis in aortic aneurysms and dissections: a mirage? Circ. Res. 120, 1718–1720 (2017).
182. Daugherty, A., Chen, Z., Sawada, H., Rateri, D. L. & Sheppard, M. B. Transforming growth factor-β in thoracic aortic aneurysms: good, bad, or irrelevant? J. Am. Heart Assoc. 6, e005221 (2017).
183. Angelov, S. N. et al. TGF-β (transforming growth factor-β) signaling protects the thoracic and abdominal aorta from angiotensin II-induced pathology by distinct mechanisms. Arterioscler. Thromb. Vasc. Biol. 37, 2102 (2017).
184. Chen, X. et al. TGF-β neutralization enhances angii-induced aortic rupture and aneurysm in both thoracic and abdominal regions. PLOS ONE 11, e0153811 (2016).
185. Wang, Y. et al. TGF-β activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J. Clin. Invest. 120, 422–432 (2010).
186. Zhang, P. et al. Smad4 deficiency in smooth muscle cells initiates the formation of aortic aneurysm. Circ. Res. 118, 388–399 (2016).
187. Gao, F. et al. Disruption of TGF-β signaling in smooth muscle cell prevents elastase-induced abdominal aortic aneurysm. Biochem. Biophys. Res. Commun. 454, 137–143 (2014).
188. Li, W. et al. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J. Clin. Invest. 124, 755–767 (2014).
189. Yang, P. et al. Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events. Sci. Rep. 6, 35444 (2016).
190. Hu, J. H. et al. Postnatal deletion of the type II transforming growth factor-β receptor in smooth muscle cells causes severe aortopathy in mice. Arterioscler. Thromb. Vasc. Biol. 35, 2647–2656 (2015).
191. Wei, H. et al. Aortopathy in a mouse model of marfan syndrome is not mediated by altered transforming growth factor β signaling. J. Am. Heart Assoc. 6, e004968 (2017).
192. van der Pluijm, I. et al. Defective connective tissue remodeling in Smad3 mice leads to accelerated aneurysmal growth through disturbed downstream TGF-β signaling. EBioMedicine 12, 280–294 (2016).
193. Dai, X. et al. SMAD3 deficiency promotes vessel wall remodeling, collagen fiber reorganization and leukocyte infiltration in an inflammatory abdominal aortic aneurysm mouse model. Sci. Rep. 5, 10180 (2015).
194. Da Ros, F. et al. Targeting interleukin-1β protects from aortic aneurysms induced by disrupted transforming growth factor β signaling. Immunity 47, 959–973 (2017).
195. Krishna, S. et al. High serum thrombospondin-1 concentration is associated with slower abdominal aortic aneurysm growth and deficiency of thrombospondin-1 promotes angiotensin II induced aortic aneurysm in mice. Clin. Sci. 131, 1261–1281 (2017).
196. Liu, Z. et al. Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. Circ. Res. 117, 129–141 (2015).
197. Krishna, S. M. et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II–infused apolipoprotein-E–deficient mouse. Arterioscler. Thromb. Vasc. Biol. 35, 389–398 (2015).
198. Kojima, Y. et al. Proefferocytic therapy promotes transforming growth factor-beta signaling and prevents aneurysm formation. Circulation 137, 750–753 (2018).
199. Li, J. et al. Diabetes reduces severity of aortic aneurysms depending on the presence of cell division autoantigen 1 (CDA1). Diabetes 67, 755–768 (2018).
200. Dai, J. et al. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine a through transforming growth factor-beta induction. PLOS ONE 6, e28903 (2011).
201. Wang, Y., Krishna, S., Walker, P. J., Norman, P. & Golledge, J. Transforming growth factor-β and abdominal aortic aneurysms. Cardiovasc. Pathol. 22, 126–132 (2013).
202. Kim, M. et al. A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients. Hum. Gene Ther. Clin. Dev. 29, 48–59 (2018).
203. Takeda, N. et al. TGF-β signaling-related genes and thoracic aortic aneurysms and dissections. Int. J. Mol. Sci. 19, E2125 (2018).
204. Golledge, J. et al. The novel association of the chemokine CCL22 with abdominal aortic aneurysm. Am. J. Pathol. 176, 2098–2106 (2010).
205. Jacomelli, J., Summers, L., Stevenson, A., Lees, T. & Earnshaw, J. J. Inequalities in abdominal aortic aneurysm screening in England: effects of social deprivation and ethnicity. Eur. J. Vasc. Endovasc. Surg. 53, 837–843 (2017).
206. 3 CT): design of a phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm. Contemp. Clin. Trials 48, 91–98 (2016).